Nurix Therapeutics IncNASDAQ:NRIX
- LAST PRICE24.7500
- TODAY'S CHANGE (%)-0.2900 (-1.1581%)
- Bid / Lots24.7000/ 6
- Ask / Lots24.7600/ 1
- Open / Previous Close25.1500 / 25.0400
- Day Range
- 52 Week Range
- Volume400,027
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRIX |
|---|---|---|
| 09:32 ET | 6720 | 25.1 |
| 09:33 ET | 1800 | 25.07 |
| 09:35 ET | 500 | 24.91 |
| 09:37 ET | 400 | 25.25 |
| 09:39 ET | 1700 | 25.28 |
| 09:42 ET | 2596 | 25.305 |
| 09:44 ET | 200 | 25.18 |
| 09:46 ET | 16013 | 25.3 |
| 09:48 ET | 2329 | 25.15 |
| 09:50 ET | 400 | 25.06 |
| 09:51 ET | 2921 | 24.86 |
| 09:53 ET | 100 | 24.84 |
| 09:55 ET | 200 | 24.82 |
| 09:57 ET | 100 | 24.82 |
| 10:00 ET | 4004 | 24.8106 |
| 10:02 ET | 1280 | 24.675 |
| 10:04 ET | 20662 | 24.68 |
| 10:06 ET | 1907 | 24.77 |
| 10:08 ET | 476 | 24.65 |
| 10:09 ET | 300 | 24.645 |
| 10:11 ET | 600 | 24.5 |
| 10:13 ET | 498 | 24.49 |
| 10:15 ET | 500 | 24.38 |
| 10:18 ET | 600 | 24.27 |
| 10:20 ET | 500 | 24.27 |
| 10:22 ET | 502 | 24.25 |
| 10:24 ET | 300 | 24.14 |
| 10:26 ET | 600 | 24.04 |
| 10:27 ET | 200 | 24.06 |
| 10:29 ET | 300 | 23.93 |
| 10:33 ET | 1200 | 23.97 |
| 10:36 ET | 5126 | 23.897 |
| 10:38 ET | 1680 | 23.985 |
| 10:40 ET | 100 | 24 |
| 10:42 ET | 700 | 24.0799 |
| 10:44 ET | 500 | 24.14 |
| 10:45 ET | 1000 | 24.15 |
| 10:47 ET | 600 | 24.0801 |
| 10:49 ET | 1726 | 24.22 |
| 10:51 ET | 300 | 24.185 |
| 10:54 ET | 800 | 24.165 |
| 10:58 ET | 100 | 24.12 |
| 11:00 ET | 2079 | 24.25 |
| 11:02 ET | 558 | 24.27 |
| 11:03 ET | 1334 | 24.25 |
| 11:07 ET | 603 | 24.27 |
| 11:09 ET | 500 | 24.255 |
| 11:12 ET | 4230 | 24.42 |
| 11:14 ET | 500 | 24.43 |
| 11:16 ET | 1499 | 24.59 |
| 11:18 ET | 1539 | 24.64 |
| 11:20 ET | 500 | 24.625 |
| 11:21 ET | 200 | 24.68 |
| 11:23 ET | 300 | 24.635 |
| 11:25 ET | 1330 | 24.62 |
| 11:27 ET | 261 | 24.74 |
| 11:30 ET | 700 | 24.89 |
| 11:32 ET | 5512 | 25 |
| 11:34 ET | 3207 | 25.0175 |
| 11:36 ET | 1450 | 25.14 |
| 11:38 ET | 2760 | 25.13 |
| 11:39 ET | 700 | 25.14 |
| 11:41 ET | 2489 | 25.21 |
| 11:43 ET | 1400 | 25.0805 |
| 11:45 ET | 504 | 25.145 |
| 11:48 ET | 1100 | 25.21 |
| 11:50 ET | 700 | 25.18 |
| 11:52 ET | 600 | 25.19 |
| 11:54 ET | 2608 | 25.01 |
| 11:56 ET | 300 | 25.06 |
| 11:57 ET | 202 | 25.11 |
| 11:59 ET | 869 | 25.03 |
| 12:01 ET | 600 | 24.86 |
| 12:03 ET | 1229 | 24.95 |
| 12:06 ET | 500 | 24.97 |
| 12:08 ET | 2937 | 24.75 |
| 12:10 ET | 809 | 24.58 |
| 12:12 ET | 300 | 24.62 |
| 12:14 ET | 400 | 24.63 |
| 12:17 ET | 610 | 24.75 |
| 12:19 ET | 600 | 24.75 |
| 12:21 ET | 200 | 24.75 |
| 12:24 ET | 2620 | 24.75 |
| 12:26 ET | 400 | 24.755 |
| 12:28 ET | 300 | 24.745 |
| 12:30 ET | 2000 | 24.755 |
| 12:32 ET | 600 | 24.725 |
| 12:33 ET | 200 | 24.74 |
| 12:35 ET | 2144 | 24.69 |
| 12:37 ET | 900 | 24.72 |
| 12:39 ET | 800 | 24.74 |
| 12:42 ET | 2921 | 24.75 |
| 12:44 ET | 400 | 24.76 |
| 12:46 ET | 1500 | 24.75 |
| 12:48 ET | 500 | 24.76 |
| 12:50 ET | 1004 | 24.72 |
| 12:51 ET | 809 | 24.71 |
| 12:53 ET | 800 | 24.705 |
| 12:55 ET | 400 | 24.7 |
| 12:57 ET | 200 | 24.66 |
| 01:00 ET | 300 | 24.69 |
| 01:02 ET | 1958 | 24.715 |
| 01:04 ET | 800 | 24.645 |
| 01:06 ET | 900 | 24.74 |
| 01:08 ET | 300 | 24.7 |
| 01:09 ET | 300 | 24.74 |
| 01:11 ET | 200 | 24.72 |
| 01:13 ET | 1300 | 24.67 |
| 01:15 ET | 997 | 24.675 |
| 01:18 ET | 500 | 24.71 |
| 01:20 ET | 200 | 24.72 |
| 01:22 ET | 600 | 24.685 |
| 01:24 ET | 1119 | 24.7 |
| 01:26 ET | 1384 | 24.64 |
| 01:27 ET | 1400 | 24.71 |
| 01:29 ET | 900 | 24.75 |
| 01:31 ET | 2700 | 24.71 |
| 01:33 ET | 100 | 24.71 |
| 01:36 ET | 505 | 24.71 |
| 01:38 ET | 100 | 24.72 |
| 01:40 ET | 300 | 24.72 |
| 01:42 ET | 1312 | 24.75 |
| 01:44 ET | 2857 | 24.72 |
| 01:45 ET | 1151 | 24.69 |
| 01:47 ET | 1400 | 24.735 |
| 01:49 ET | 3146 | 24.76 |
| 01:51 ET | 600 | 24.7 |
| 01:54 ET | 3521 | 24.67 |
| 01:58 ET | 200 | 24.73 |
| 02:00 ET | 200 | 24.72 |
| 02:02 ET | 2635 | 24.75 |
| 02:03 ET | 4523 | 24.92 |
| 02:05 ET | 300 | 24.895 |
| 02:07 ET | 600 | 24.86 |
| 02:09 ET | 300 | 24.89 |
| 02:12 ET | 1348 | 24.83 |
| 02:14 ET | 11513 | 24.7 |
| 02:16 ET | 16836 | 24.75 |
| 02:18 ET | 20090 | 24.77 |
| 02:20 ET | 2014 | 24.8 |
| 02:23 ET | 2069 | 24.84 |
| 02:25 ET | 5604 | 24.82 |
| 02:27 ET | 150 | 24.77 |
| 02:30 ET | 1903 | 24.775 |
| 02:32 ET | 900 | 24.78 |
| 02:34 ET | 4965 | 24.92 |
| 02:36 ET | 160 | 24.95 |
| 02:38 ET | 360 | 24.91 |
| 02:41 ET | 300 | 24.92 |
| 02:43 ET | 1380 | 24.92 |
| 02:45 ET | 700 | 24.915 |
| 02:48 ET | 1014 | 24.92 |
| 02:50 ET | 2279 | 24.89 |
| 02:52 ET | 3606 | 24.805 |
| 02:54 ET | 600 | 24.805 |
| 02:56 ET | 200 | 24.78 |
| 02:57 ET | 2200 | 24.73 |
| 02:59 ET | 846 | 24.66 |
| 03:01 ET | 1343 | 24.75 |
Today
Oct 31, 2024
Nurix Therapeutics to Participate in Upcoming Investor Conferences, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 24, 2024
DJ Nurix Therapeutics Initiated at Buy by UBS, from 7:55AM ET on Thursday Oct 24, 2024 by Dow Jones
7:55AM ET on Thursday Oct 24, 2024 by Dow Jones
Oct 21, 2024
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit, from 4:00PM ET on Monday Oct 21, 2024 by Dow Jones
4:00PM ET on Monday Oct 21, 2024 by Dow JonesDJ Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham, from 7:25AM ET on Monday Oct 21, 2024 by Dow Jones
7:25AM ET on Monday Oct 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nurix Therapeutics Inc | 1.8B | -8.5x | --- |
Arvinas Inc | 1.8B | -5.5x | --- |
Recursion Pharmaceuticals Inc | 1.9B | -4.1x | --- |
Tarsus Pharmaceuticals Inc | 1.8B | -10.3x | --- |
WAVE Life Sciences Ltd | 2.0B | -23.3x | --- |
Bicycle Therapeutics PLC | 1.6B | -7.3x | --- |
Company Information
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Contact Information
- Headquarters
- 1700 Owens St Ste 205SAN FRANCISCO, CA, United States 94158-0006
- Phone
- 415-660-5320
- Fax
- 415-525-4200
Executives
- Independent Chairman of the Board
- Julia Gregory
- President, Chief Executive Officer, Director
- Arthur Sands
- Chief Financial Officer
- Hans van Houte
- Chief Technical Officer
- Pasit Phiasivongsa
- Chief Scientific Officer
- Gwenn Hansen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8B |
|---|---|
Revenue (TTM) | $56.4M |
Shares Outstanding | 70.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.20 |
EPS | $-2.91 |
Book Value | $4.12 |
P/E Ratio | -8.5x |
Price/Sales (TTM) | 31.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -343.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
